tiprankstipranks
Trending News
More News >
Inozyme Pharma (INZY)
NASDAQ:INZY
US Market

Inozyme Pharma (INZY) AI Stock Analysis

Compare
788 Followers

Top Page

IN

Inozyme Pharma

(NASDAQ:INZY)

Rating:37Underperform
Price Target:
Inozyme Pharma's stock score reflects its early-stage biotechnology status with significant operational losses, zero revenue, and ongoing cash burn. Technical indicators show short-term momentum but highlight potential overbought conditions. The negative P/E ratio underscores the lack of profitability, and with no earnings data or corporate events provided, the score is primarily driven by weak financial performance.
Positive Factors
Clinical Data
Recent interim data from INZY showed a significant increase in a key phosphate biomarker, which is seen as derisking future clinical endpoints and enhancing the potential for regulatory approval.
Strategic Acquisition
The acquisition of Inozyme Pharma, Inc. by BMRN is expected to strengthen BMRN's enzyme replacement therapy portfolio with the addition of INZ-701.
Negative Factors
Financing Environment
Inozyme required capital ahead of pivotal data and faced a difficult financing environment.
Valuation Concerns
The acquisition price is considered discounted likely due to risks associated with adult opportunities and cash overhang.

Inozyme Pharma (INZY) vs. SPDR S&P 500 ETF (SPY)

Inozyme Pharma Business Overview & Revenue Model

Company DescriptionInozyme Pharma (INZY) is a biopharmaceutical company focused on developing novel therapeutics for the treatment of rare diseases characterized by abnormal mineralization. The company aims to address conditions that lead to significant morbidities and mortality due to a lack of effective treatments. Inozyme Pharma's core product candidates target enzyme deficiencies that cause abnormal mineralization in the body, impacting bones, blood vessels, and soft tissues.
How the Company Makes MoneyInozyme Pharma makes money primarily through the development and commercialization of its proprietary therapies aimed at treating rare mineralization disorders. The company's revenue model includes potential income from product sales, should its therapies receive regulatory approval and reach the market. Additionally, Inozyme may engage in partnerships or collaborations with larger pharmaceutical companies to co-develop products or out-license their technologies, which could provide upfront payments, milestone payments, and royalties. As a company focused on clinical-stage development, Inozyme may also receive funding through research grants and investments to support ongoing clinical trials and further drug development.

Inozyme Pharma Financial Statement Overview

Summary
Inozyme Pharma is in a typical early-stage biotechnology phase, characterized by zero revenue and significant operational losses. While its cash reserves and manageable debt levels provide some financial resilience, the ongoing negative cash flows and lack of revenue generation highlight the need for successful product development and commercialization to ensure long-term viability.
Income Statement
20
Very Negative
Inozyme Pharma has consistently reported zero revenue over the years, indicating its early-stage status typical in biotechnology. The company has faced increasing EBIT and net income losses over the years, highlighting challenges in managing operational efficiency and profitability.
Balance Sheet
40
Negative
The company has a relatively low debt-to-equity ratio, suggesting prudent leverage management. However, declining stockholders' equity and increasing liabilities could pose risks to financial stability. Despite this, the company maintains a healthy cash position.
Cash Flow
35
Negative
Operating cash flow has become increasingly negative over the years, reflecting operational cash burn, which is common in biotech firms without revenue. Despite negative free cash flow, the company has managed to raise significant financing cash flows, mitigating liquidity concerns temporarily.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue0.000.000.000.000.000.00
Gross Profit-195.00K0.00-1.29M-1.18M-1.05M-217.00K
EBITDA-100.34M-104.03M-74.81M-65.88M-55.97M-56.82M
Net Income-106.72M-102.02M-71.17M-65.45M-56.41M-55.84M
Balance Sheet
Total Assets95.16M123.18M200.85M139.19M123.54M169.36M
Cash, Cash Equivalents and Short-Term Investments84.78M113.09M188.59M127.87M111.80M159.90M
Total Debt26.37M46.87M46.59M6.78M3.37M1.29M
Total Liabilities63.37M65.36M60.37M20.80M14.27M11.26M
Stockholders Equity31.80M57.83M140.48M118.59M109.27M158.10M
Cash Flow
Free Cash Flow-96.55M-91.97M-70.97M-58.17M-48.55M-36.54M
Operating Cash Flow-96.52M-91.91M-70.67M-57.76M-48.15M-35.97M
Investing Cash Flow90.29M67.00M-53.65M-5.40M42.80M-117.18M
Financing Cash Flow11.47M11.40M125.97M72.79M609.00K149.81M

Inozyme Pharma Technical Analysis

Technical Analysis Sentiment
Positive
Last Price4.00
Price Trends
50DMA
2.85
Positive
100DMA
1.98
Positive
200DMA
2.79
Positive
Market Momentum
MACD
0.27
Positive
RSI
82.70
Negative
STOCH
88.89
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INZY, the sentiment is Positive. The current price of 4 is above the 20-day moving average (MA) of 3.99, above the 50-day MA of 2.85, and above the 200-day MA of 2.79, indicating a bullish trend. The MACD of 0.27 indicates Positive momentum. The RSI at 82.70 is Negative, neither overbought nor oversold. The STOCH value of 88.89 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for INZY.

Inozyme Pharma Risk Analysis

Inozyme Pharma disclosed 81 risk factors in its most recent earnings report. Inozyme Pharma reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Inozyme Pharma Peers Comparison

Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
ININO
51
Neutral
$74.82M-132.44%-60.52%42.41%
49
Neutral
AU$2.48B4.33-64.25%2.85%36.51%13.14%
47
Neutral
$66.90M-66.30%30.51%
43
Neutral
$90.92M-138.78%32.77%
41
Neutral
$59.80M-273.36%883.05%62.93%
38
Underperform
$46.86M-130.16%65.54%
37
Underperform
$258.25M-141.69%-17.06%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
INZY
Inozyme Pharma
4.00
-0.49
-10.91%
INO
Inovio Pharmaceuticals
2.14
-6.79
-76.04%
ADAP
Adaptimmune Therapeutics
0.24
-0.98
-80.33%
VTVT
vTv Therapeutics
15.06
-2.52
-14.33%
PYXS
Pyxis Oncology
1.20
-1.70
-58.62%
IOBT
IO Biotech
1.49
0.29
24.17%

Inozyme Pharma Corporate Events

Product-Related AnnouncementsBusiness Operations and Strategy
Inozyme Pharma Advances with Promising Trial Results
Positive
Jan 10, 2025

Inozyme Pharma announced positive interim results for its INZ-701 treatment from the ENERGY 1 trial and Expanded Access Program, demonstrating improved survival rates, reduced arterial calcifications, and improved heart function in infants and young children with ENPP1 Deficiency. The company completed enrollment in the ENERGY 3 pivotal trial and received regulatory guidance for the upcoming ASPIRE pivotal trial focused on ABCC6 Deficiency in children, highlighting significant advancements in their therapeutic programs and underscoring the potential impact on addressing unmet medical needs in these patient populations.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 03, 2025